Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and bromopyruvate

sorafenib has been researched along with bromopyruvate in 3 studies

Compound Research Comparison

Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010)
(sorafenib)		Studies
(bromopyruvate)		Trials
(bromopyruvate)		Recent Studies (post-2010) (bromopyruvate)
6,5207305,2513250205

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Garcia-Manero, G; Hu, Y; Huang, A; Huang, P; Ju, HQ; Liu, D; Liu, K; Wen, S; Zhan, G1
Chang, Y; Cho, EJ; Cho, H; Cho, YY; Jo, A; Kim, JB; Kim, YJ; Lee, JH; Lee, M; Lee, S; Nam, JY; Yoon, JH; Yu, SJ1
Cho, EJ; Cho, YY; Kim, K; Kim, YJ; Lee, JH; Lee, YB; Na, J; Yoo, JJ; Yoon, JH; Youn, H; Yu, SJ1

Other Studies

3 other study(ies) available for sorafenib and bromopyruvate

ArticleYear
Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation.
    Cancer letters, 2016, 07-28, Volume: 377, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxyglucose; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; G2 Phase Cell Cycle Checkpoints; Genetic Predisposition to Disease; Glycolysis; Humans; Leukemia, Myeloid, Acute; Mice; Mitochondria; Mutation; Niacinamide; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; Pyruvates; Signal Transduction; Sorafenib; Tandem Repeat Sequences; Time Factors

2016
3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells.
    PloS one, 2017, Volume: 12, Issue:3

    Topics: Anoikis; Antineoplastic Agents; Buthionine Sulfoximine; Carcinoma, Hepatocellular; Epithelial-Mesenchymal Transition; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyruvates; Reactive Oxygen Species; Sorafenib

2017
Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma.
    International journal of molecular sciences, 2019, Mar-14, Volume: 20, Issue:6

    Topics: Animals; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Hexokinase; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Prognosis; Pyruvates; Sorafenib; Survival Analysis; Treatment Outcome; Up-Regulation; Xenograft Model Antitumor Assays

2019